EU Approves Enhertu for HER2-Low Breast Cancer
Ticker: AZN · Form: 6-K · Filed: Apr 4, 2025 · CIK: 901832
| Field | Detail |
|---|---|
| Company | Astrazeneca PLC (AZN) |
| Form Type | 6-K |
| Filed Date | Apr 4, 2025 |
| Risk Level | low |
| Sentiment | bullish |
Sentiment: bullish
Topics: regulatory-approval, drug-launch, oncology
TL;DR
EU greenlights Enhertu for more HER2-low breast cancer patients, big win for AstraZeneca.
AI Summary
AstraZeneca PLC announced on April 4, 2025, that Enhertu has received European Union approval for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or 2+/ISH-) breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. This marks a significant expansion of Enhertu's use in breast cancer.
Why It Matters
This EU approval expands access to a potentially life-extending treatment for a broader group of breast cancer patients, impacting thousands of individuals and their healthcare providers across Europe.
Risk Assessment
Risk Level: low — This filing is an informational report of a regulatory approval, not a financial event that inherently carries significant risk.
Key Players & Entities
- AstraZeneca PLC (company) — Registrant and developer of Enhertu
- Enhertu (drug) — Medication approved in the EU
- European Union (jurisdiction) — Region of approval
- April 4, 2025 (date) — Date of announcement
FAQ
What specific criteria define HER2-low breast cancer for Enhertu's approval?
HER2-low is defined as IHC 1+ or 2+/ISH-.
What prior treatments are required for eligibility in the EU?
Patients must have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.
What is the filing type and date?
The filing is a Form 6-K, filed on April 4, 2025.
What is AstraZeneca's central index key?
AstraZeneca's central index key is 0000901832.
What was AstraZeneca's former company name?
AstraZeneca's former company name was ZENECA GROUP PLC.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 4, 2025 regarding ASTRAZENECA PLC (AZN).